Preclinical studies demonstrated an immune-boosting effect by traditional chemotherapy: cisplatin can increase major histocompatibility complex (MHC) class I expression [21]: doxorubicin enhances antigen-specific CD8 T-Cell proliferation and tumor infiltration [22], and cyclophosphamide induces Treg depletion [23]. This evidence concerns the gene CD8A and neoplasm.